KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Raw Materials (2016 - 2026)

Pacific Biosciences Of California has reported Raw Materials over the past 15 years, most recently at $38.6 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 14.65% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $38.6 million, down 14.65%, while the annual FY2025 figure was $38.6 million, 14.65% down from the prior year.
  • Raw Materials for Q4 2025 was $38.6 million at Pacific Biosciences Of California, down from $41.8 million in the prior quarter.
  • Over five years, Raw Materials peaked at $46.0 million in Q2 2025 and troughed at $4.5 million in Q1 2021.
  • A 5-year average of $26.1 million and a median of $25.2 million in 2023 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: surged 202.0% in 2022 and later decreased 14.65% in 2025.
  • Year by year, Raw Materials stood at $8.0 million in 2021, then surged by 202.0% to $24.1 million in 2022, then skyrocketed by 34.36% to $32.4 million in 2023, then surged by 39.58% to $45.3 million in 2024, then decreased by 14.65% to $38.6 million in 2025.
  • Business Quant data shows Raw Materials for PACB at $38.6 million in Q4 2025, $41.8 million in Q3 2025, and $46.0 million in Q2 2025.